These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 16163378

  • 1. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.
    Kanai R, Tomita H, Shinoda A, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T.
    Gene Ther; 2006 Jan; 13(2):106-16. PubMed ID: 16163378
    [Abstract] [Full Text] [Related]

  • 2. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
    Kanai R, Eguchi K, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T.
    J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
    [Abstract] [Full Text] [Related]

  • 3. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
    Kanai R, Tomita H, Hirose Y, Ohba S, Goldman S, Okano H, Kawase T, Yazaki T.
    Hum Gene Ther; 2007 Jan; 18(1):63-73. PubMed ID: 17238803
    [Abstract] [Full Text] [Related]

  • 4. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
    Kambara H, Okano H, Chiocca EA, Saeki Y.
    Cancer Res; 2005 Apr 01; 65(7):2832-9. PubMed ID: 15805284
    [Abstract] [Full Text] [Related]

  • 5. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
    Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL.
    Gene Ther; 2000 May 01; 7(10):867-74. PubMed ID: 10845725
    [Abstract] [Full Text] [Related]

  • 6. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL.
    Cancer Gene Ther; 2000 Feb 01; 7(2):275-83. PubMed ID: 10770637
    [Abstract] [Full Text] [Related]

  • 7. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
    Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS.
    Gene Ther; 2003 Feb 01; 10(4):292-303. PubMed ID: 12595888
    [Abstract] [Full Text] [Related]

  • 8. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
    Samoto K, Perng GC, Ehtesham M, Liu Y, Wechsler SL, Nesburn AB, Black KL, Yu JS.
    Cancer Gene Ther; 2001 Apr 01; 8(4):269-77. PubMed ID: 11393279
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
    Todo T, Rabkin SD, Martuza RL.
    Cancer Gene Ther; 2000 Jun 01; 7(6):939-46. PubMed ID: 10880026
    [Abstract] [Full Text] [Related]

  • 10. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
    Kim SH, Wong RJ, Kooby DA, Carew JF, Adusumilli PS, Patel SG, Shah JP, Fong Y.
    Eur J Cancer; 2005 Jan 01; 41(2):313-22. PubMed ID: 15661558
    [Abstract] [Full Text] [Related]

  • 11. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
    Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL.
    Mol Ther; 2000 Dec 01; 2(6):588-95. PubMed ID: 11124059
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
    Nakano K, Todo T, Chijiiwa K, Tanaka M.
    Mol Ther; 2001 Apr 01; 3(4):431-7. PubMed ID: 11319903
    [Abstract] [Full Text] [Related]

  • 13. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.
    Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y.
    Cancer Gene Ther; 2002 Nov 01; 9(11):935-45. PubMed ID: 12386832
    [Abstract] [Full Text] [Related]

  • 14. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M, Rabkin SD, Martuza RL.
    Cancer Res; 2007 Jan 15; 67(2):440-4. PubMed ID: 17234749
    [Abstract] [Full Text] [Related]

  • 15. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
    Chung RY, Saeki Y, Chiocca EA.
    J Virol; 1999 Sep 15; 73(9):7556-64. PubMed ID: 10438845
    [Abstract] [Full Text] [Related]

  • 16. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
    Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA.
    Gene Ther; 2007 Jul 15; 14(13):1045-54. PubMed ID: 17429445
    [Abstract] [Full Text] [Related]

  • 17. HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation.
    Saydam O, Saydam N, Glauser DL, Pruschy M, Dinh-Van V, Hilbe M, Jacobs AH, Ackermann M, Fraefel C.
    Gene Ther; 2007 Aug 15; 14(15):1143-51. PubMed ID: 17495946
    [Abstract] [Full Text] [Related]

  • 18. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
    Todo T, Martuza RL, Rabkin SD, Johnson PA.
    Proc Natl Acad Sci U S A; 2001 May 22; 98(11):6396-401. PubMed ID: 11353831
    [Abstract] [Full Text] [Related]

  • 19. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
    Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS.
    Int J Oncol; 2007 Nov 22; 31(5):1177-85. PubMed ID: 17912445
    [Abstract] [Full Text] [Related]

  • 20. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
    Liu TC, Wakimoto H, Martuza RL, Rabkin SD.
    Clin Cancer Res; 2007 Oct 01; 13(19):5897-902. PubMed ID: 17908985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.